Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-34

This would be a problem for registration of bisantrene, but it is not a problem from a practical perspective. Any oncologist wanting to use bisantrene off-label in AML would look at the overall results and use the best combination. Let’s say we are lucky and we can get 60% of these patients bridged to a transplant, then this is what the oncologists want to know and be able to tell their patients. While we might not know exactly how much bisantrene is adding to the success of the combination, the oncologist will know the overall response rate and the side effects to expect from the combination.